Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.

HER2/neu-derived peptides inducing MHC class II-restricted CD4+ T helper lymphocyte (Th) responses, although critical for tumour rejection, are not thoroughly characterized. Here, we report the generation and characterization of CD4+ T cell clones specifically recognizing a HER-2/neu-derived peptide (776-788) [designated HER2(776-788)]. Such clones yielded specific proliferative and cytokine [gamma-interferon(IFN)-gamma] responses when challenged with autologous dendritic cells (DCs) loaded with HER2(776-788). By performing blocking studies with monoclonal antibodies (MAbs) and by using DCs from allogeneic donors sharing certain HLA-DR alleles, we found that HER2(776-788) is a promiscuous peptide presented, at least, by DRB5*0101, DRB1*0701 and DRB1*0405 alleles. One TCRV beta 6.7+ clone recognized the HLA-DRB5*0101+ FM3 melanoma cell line transfected with a full length HER-2/neu cDNA. Moreover, this clone recognized the HER-2/neu+ SKBR3 breast cancer cell line induced to express HLA-DR, thus demonstrating that HER2(776-788) represents a naturally processed and presented epitope. Our data demonstrate that helper peptide HER2(776-788) represents a promiscuous epitope binding to at least three HLA-DR alleles, thus offering a broad population coverage. The use of antigenic peptides presented by major histocompatibility complex (MHC) class II in addition to those presented by class I may improve the therapeutic efficacy of active immunization.
AuthorsR Sotiriadou, S A Perez, A D Gritzapis, P A Sotiropoulou, H Echner, S Heinzel, A Mamalaki, G Pawelec, W Voelter, C N Baxevanis, M Papamichail
JournalBritish journal of cancer (Br J Cancer) Vol. 85 Issue 10 Pg. 1527-34 (Nov 16 2001) ISSN: 0007-0920 [Print] Scotland
PMID11720440 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Neoplasm
  • Epitopes, T-Lymphocyte
  • HER2(776-788)
  • HLA-DR Antigens
  • Peptide Fragments
  • Peptides
  • Interferon-gamma
  • Receptor, ErbB-2
  • Antigen Presentation
  • Antigens, Neoplasm (immunology)
  • Cell Line
  • Cells, Cultured
  • Clone Cells
  • Epitopes, T-Lymphocyte (immunology)
  • HLA-DR Antigens (physiology)
  • Humans
  • Interferon-gamma (biosynthesis)
  • Lymphocyte Activation
  • Neoplasms (immunology)
  • Peptide Fragments (immunology)
  • Peptides (immunology)
  • Receptor, ErbB-2 (immunology)
  • T-Lymphocytes, Cytotoxic (immunology)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: